US Patent

US9023897 — Biodegradable drug delivery compositions

Formulation · Assigned to MedinCell SA · Expires 2033-04-05 · 7y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a biodegradable drug delivery composition containing a triblock copolymer and a diblock copolymer, along with a pharmaceutically active principle.

USPTO Abstract

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.

Drugs covered by this patent

Risperdal (risperidone) · Johnson & Johnson (Janssen)

Patent Metadata

Patent number: US9023897
Jurisdiction: US
Classification: Formulation
Expires: 2033-04-05
Drug substance claim: No
Drug product claim: Yes
Assignee: MedinCell SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.